

PII: S0960-894X(96)00494-5

## Synthesis and Biological Properties of Partially Modified Retro and Retro-inverso Pseudo Peptides of Arg-Gly-Asp (RGD)

Naoyuki Nishikawa,\*<sup>†</sup> Hiroyuki Komazawa,<sup>†</sup> Atsushi Orikasa,<sup>†</sup> Mitsuo Yoshikane,<sup>†</sup> Jiro Yamaguchi,<sup>†</sup> Masayoshi Kojima,<sup>†</sup> Mitsunori Ono,<sup>†</sup> Isamu Itoh,<sup>†</sup> Ichiro Azuma,<sup>††</sup> Hideki Fujii,<sup>†††</sup> Jun Murata<sup>†††</sup> Ikuo Saiki,<sup>†††</sup>

<sup>†</sup> Ashigara Research Laboratories, Fuji Photo Film Co., Ltd., Minamiashigara, Kanagawa 250-01, Japan <sup>††</sup> Institute of Immunological Science, Hokkaido University, Sapporo, Hokkaido 060, Japan <sup>†††</sup> Department of Pathogenic Biochemistry, Research Institute for WAKAN-YAKU, Toyama Medical Pharmaceutical University, Sugitani, Toyama 930-01, Japan

**Abstract:** Partially modified retro and retro-inverso peptide analogs of Arg-Gly-Asp (RGD) were synthesized and examined their inhibitory effects on experimental lung metastasis of murine melanoma and adenosine 5'-diphosphate (ADP) induced platelet aggregation. The analogs showed efficient therapeutic potency for the tumor metastasis but low inhibitory effect on ADP induced platelet aggregation. Copyright © 1996 Elsevier Science Ltd

Interaction of tumor cells with extracellar matrix plays an important role in the complex process of cancer metastasis. The Arg-Gly-Asp (RGD) sequence is a cell binding unit of adhesion molecules and extracellar matrix components such as fibronectin, vitronectin and fibrinogen, and recognized by integrin receptors on the cell surface. Humphries et al. have reported that synthetic oligopeptide containing the RGD sequence inhibited metastasis of murine melanoma.<sup>1</sup> However, high dose of the peptide was required for effective inhibition of the metastasis because of the rapid degradation and clearance *in vivo*. To overcome this problem, we developed conjugations of cell-adhesive peptides with various drug carriers such as poly (ethylene glycol)<sup>2</sup> or chitin derivatives.<sup>3</sup> We also reported that liposomes having RGD related peptides on the surface showed high anti-metastatic efficacy.<sup>4</sup> Recently, syntheses of the pseudo peptides have been studied extensively to avoid enzymatic degradation *in vivo*. Since the Arg-Gly linkage of the sequence has been reported as a easy degradable linkage,<sup>5</sup> we designed the partially modified retro and retro-inverso pseudo peptides<sup>6</sup> of the RGD peptide (1a and 1b) reversing amide bond between arginyl and glycyl residue. The RGD related peptides are also concerned with platelet aggregation. In this paper, we wish to describe the synthesis, the anti-metastatic effects and the anti-platelet aggregation activities of the pseudo peptides.



1a: Partially modified retro peptide



1b: Partially modified retro-inverso peptide

## N. NISHIKAWA et al.

 $N^{\omega}$ -2,4,6-trimethylbenzenesulfonyl-L-arginine benzyl ester hydrochloride (Arg(Mts)-OBzl•HCl) was prepared from  $N^{\alpha}$ -Boc- $N^{\omega}$ -2,4,6-trimethylbenzenesulfonyl-L-arginine (Boc-Arg(Mts)) by using general method (Scheme 1).  $N^{\omega}$ -toluensulfonyl-D-arginine benzyl ester hydrochloride (D-Arg(Tos)-OBzl·HCl) was prepared by similar way using  $N^{\alpha}$ -Boc- $N^{\omega}$ -toluensulfonyl-D-arginine (Boc-D-Arg(Tos)). Scheme 2 shows synthetic routes of the pseudo peptides. Malonic acid (2) was converted to protected pseudo peptides (**3a** and **3b**) by sequential peptide couplings using diphenylphosphorylazide (DPPA)<sup>7</sup> in DMF at room temperature. After purification using silica gel chromatography (eluent: AcOEt), the protected pseudo peptides were treated with 1M trifluoromethanesulfonic acid (TFMSA)-thioanisole-*m*-cresol / TFA solution<sup>8</sup> to remove all protecting groups. The products were passed over an ion exchange column (Amberlite<sup>®</sup> IRA-400 (Cl<sup>-</sup>)), then they were purified by a reverse-phase HPLC using a ODS column (eluent: 0.1 % AcOH aqueous solution). The pseudo peptides **1a** and **1b** were obtained as acetates and characterized by <sup>1</sup>H NMR, FAB-MS and elemental analysis.<sup>9</sup>

Scheme 1

Scheme 2 OBzl BZIC OBzl 0 0 O HN NH a. b Mts 3a 0 0 a. 2 c. d **BzlO** OBzl 1b Ò 0 OBzl Ο Tos 3b

(a) DPPA, Asp(OBzI)2•TosOH, Et3N, DMF; (b) DPPA, Arg(Mts)-OBzI•HCI, Et3N, DMF; (c) TFMSA, thioanisole, *m*-cresol,TFA; (d) Amberlite® IRA-400 (CI-); (e) DPPA, D-Arg(Tos)-OBzI•HCI, Et3N, DMF

Table 1 shows the inhibitory effect of the partially modified retro and retro-inverso pseudo peptides (1a and 1b) on the experimental metastasis of the murine B16-BL6 melanoma.<sup>2, 3</sup> Both of the pseudo peptides showed effective inhibition of tumor metastasis, while the Arg-Gly-Asp-Ser at the same dose did not

show significant efficacy. Although the partially modified retro analog **1a** has opposite chirality against the natural peptide at arginyl residue, it shows comparable anti-metastic efficacy to the partially modified retroinverso analog **1b** having the same chirality of the natural peptide. Pierschbacher and Ruoslahti revealed that the replacement of L-Arg with D-Arg in Gly-Arg-Gly-Asp-Ser-Pro-Cys was tolerated against the ability of the peptide to inhibit the attachment of cells to a fibronectin substrate.<sup>10</sup> These results suggest that the stereochemistry of the arginyl residue of the RGD peptide is not concerned with recognition of the receptor. To estimate the stability of **1a** against enzymatic degradation in the circulation, time-dependent decomposition of **1a** in plasma was determined at 37°C. The partially modified retro analog **1a** was scarcely degraded during 6h incubation period, but the RGDS peptide was degraded up to 80% in this condition. We speculate that resistance to the enzymatic degradation would prolong life time of the pseudo peptide *in vivo*. As the result, the pseudo peptide would show higher anti-metastatic potency than the RGDS peptide.

Sample	Dose (µg/mouse)	No. of lung metastasi Mean ± SD	s on day 14 (Range)
 Untreated (PBS)		101±14	( 61-133)
RGDS	500	93±45	( 44-154)
retro peptide 1a	500	19±11	( 4- 36)
retro-inverso peptide 1b	500	38± 3	(19-63)

 
 Table 1. Effect of Retro and Retro-inverso Peptides of RGD on Experimental Lung Metastasis Produced by i.v. Injection of B16-BL6 Melanoma.

Five C57BL/6 mice per group were administered i.v. with the peptide analogs and B16-BL6 melanoma  $(7x10^4)$  cells. After 2 weeks from administration, tumor colonies in lung were counted.

RGD sequence of the adhesive molecule is also recognized by the glycoprotein IIb/IIIa (GPIIb/IIIa) which appears on the surface of the activated platelet. It is well known that various peptides having RGD sequence inhibit the platelet aggregation. Table 2 shows inhibitory effects of the pseudo peptides and the RGDS peptide on ADP-induced human platelet aggregation *in vitro*.<sup>11</sup> The partially modified retro analog **1a** showed slight inhibitory effect on the platelet aggregation (IC<sub>50</sub>=2.4 mM), which is one order less potent than the RGDS peptide (IC<sub>50</sub>=0.18 mM). The partially modified retro-inverso analog **1b** also showed similar low inhibitory activity comparable with **1a**. These results suggest that the partially modified retro and retro-inverso peptides of the RGD peptide show low binding affinity to a GPIIb/IIIa receptor.

 Table 2. Inhibition of ADP-Induced Human Platelet Aggregation

 by Retro and Retro-inverso Peptides

Sample	IC <sub>50</sub> (mM)	% inhibition at 1mg / ml
RGDS	0.18	100%
retro peptide 1a	2.4	57%
retro-inverso peptide 1b	n.d. <sup>a</sup>	53%

a) no data.

In conclusion, the partially modified retro and retro-inverso analogs of the RGD peptide showed higher inhibitory effect on the experimental lung metastasis in mice but lower inhibitory activity on ADPinduced human platelet aggregation comparing with the natural RGDS peptide, which means selective increase on the anti-metastatic activity was obtained by using the pseudo peptides. We are now proceeding to investigate their biological properties in detail.

Acknowledgment: This work was supported in part by Grants-in-Aid for Cancer Research from the Japanese Ministry of Education, Science and Culture (No. 06282122 & 07273106).

## **References and Notes**

- 1. Humphries, M.; Olden, J. K.; Yamada, K. M. Science 1986, 233, 467.
- 2. Komazawa, H.; Saiki, İ.; Igarashi, Y.; Azuma, I.; Kojima, M.; Orikasa, A.; Ono, M.; Itoh, I. J. Bioac. Comp. Poly. 1993, 8, 258.
- (a) Komazawa, H.; Saiki, I.; Igarashi, Y.; Azuma, I.; Tokura, S.; Kojima, M.; Orikasa, A.; Ono, M.; Itoh, I. Carbohydrate poly. 1993, 21, 299. (b) Komazawa, H.; Saiki, I.; Nishikawa, N.; Yoneda, J.; Yoo, Y.C.; Kojima, M.; Orikasa, A.; Ono, M.; Itoh, I.; Nishi, N.; Tokura, S.; Azuma, I. Clin. Exp. Metastasis 1993, 11, 482. (c) Nishikawa, N.; Komazawa, H.; Kojima, M.; Ono, M.; Itoh, I.; Saiki, I.; Fujii, H.; Azuma, I.; Nishi, N.; Tokura, S. In Peptide Chem. 1995; Nishi, N., ed.; Protein Research Foundation: Osaka, 1996; pp 389-392.
- Oku, N.; Tokudome, Y.; Koike, C.; Nishikawa, N.; Mori, H.; Saiki, I.; Okada, S. Life Sciences 1996, 58, 2263.
- 5. Lorand, L. In *Methods in Enzymology*; Academic Press: New York, 1981; 80, Part C.
- 6. Durr, H.; Goodman, M.; Gunther, J. Angew. Chem. Int. Ed. Engl. 1992, 31, 785.
- 7. Shioiri, T.; Ninomiya, K.; Yamada, S. J. Am. Chem. Soc. 1972, 94, 6203.
- 8. Yajima, H.; Fujii, N. J. Am. Chem. Soc. 1981, 103, 5867.
- Based on the elemental analysis, the products will contain some moisture. Data for 1a. <sup>1</sup>H-NMR (600MHz, H<sub>2</sub>O/D<sub>2</sub>O=9/1, pH=6.9, 278K), 1.58-1.68 (m, 2H, Arg γCH<sub>2</sub>), 1.72-1.78 (m, 1H, Arg βCH<sub>2</sub>), 1.86-1.92 (m, 1H, Arg βCH<sub>2</sub>), 1.93 (s, 3H, AcO<sup>-</sup>), 2.54 (dd, 1H, J=10.4, 16.0Hz, Asp βCH<sub>2</sub>), 2.75 (dd, 1H, J=3.4, 16.0Hz, Asp βCH<sub>2</sub>), 3.20 (br s, 2H, Arg δCH<sub>2</sub>), 3.30 (d, 1H, J=15.7Hz, CO-CH<sub>2</sub>-CO), 3.49 (d, 1H, J=15.7Hz, CO-CH<sub>2</sub>-CO), 4.20 (ddd, 1H, J=4.2, 7.4, 8.0Hz, Arg αCH), 4.44 (ddd, 1H, J=3.4, 7.4, 10.4Hz, Asp αCH), 6.59 (br s, 2H, Arg NH<sub>2</sub>CNH<sub>2</sub><sup>+</sup>), 6.90 (br s, 2H, Arg αNH<sub>2</sub>; FAB-MS (M+H)<sup>+</sup>=376; Anal. Calcd for C<sub>13</sub>H<sub>10</sub>O<sub>2</sub>N<sub>5</sub>·CH<sub>3</sub>COOH·1/2H<sub>2</sub>O; C%, 40.54; H%, 5.90; N%, 15.76: Found. C%, 39.59; H%, 5.49, N%, 16.08. Data for 1b. <sup>1</sup>H-NMR (600MHz, H<sub>2</sub>O:D<sub>2</sub>O=9:1, pH=6.9, 278K) 1.58-1.70 (m, 2H, Arg γCH<sub>2</sub>), 1.72-1.80 (m, 1H, Arg βCH<sub>2</sub>), 1.86-1.92 (m, 1H, Arg βCH<sub>2</sub>), 1.93 (s, 3H, AcO<sup>-</sup>), 2.55 (dd, 1H, J=10.1,

16.0Hz, Asp  $\beta$ CH<sub>2</sub>), 2.73 (dd, 1H, J=3.5, 16.0Hz, Asp  $\beta$ CH<sub>2</sub>), 3.21 (br s, 2H, Arg  $\delta$ CH<sub>2</sub>), 3.34 (d, 1H, J=15.7Hz, CO-CH<sub>2</sub>-CO), 3.44 (d, 1H, J=15.7Hz, CO-CH<sub>2</sub>-CO), 4.21 (ddd, 1H, J=4.5, 7.5, 8.0Hz, Arg  $\alpha$ CH), 4.43 (ddd, 1H, J=3.5, 7.4, 10.1Hz, Asp  $\alpha$ CH), 6.55 (br s, 2H, Arg NH<sub>2</sub>CNH<sub>2</sub>+), 6.93 (br s, 2H, Arg  $\alpha$ NH<sub>2</sub>CNH<sub>2</sub>+), 7.43 (br s, 1H, Arg  $\alpha$ NH), 8.46 (d, 1H, J=7.4Hz, Asp  $\alpha$ NH), 8.47 (d, 1H, J=7.5Hz, Arg  $\alpha$ NH); FAB-MS (M+H)+=376; Anal. Calcd for C<sub>13</sub>H<sub>10</sub>O<sub>2</sub>N<sub>5</sub>·CH<sub>3</sub>COOH·1/2H<sub>2</sub>O; C%, 40.54; H%, 5.90; N%, 15.76: Found. C%, 40.04; H%, 5.47, N%, 16.12.

- 10. Pierschbacher, M. D.; Ruoslahti, E. J. Biol. Chem. 1987, 262, 17294.
- 11. Born, G.V.R. Nature 1962, 194, 927.

(Received in Japan 20 August 1996; accepted 15 October 1996)